In summary, while both adjuvant atezolizumab and pembrolizumab can be offered to non-ALK and non-EGFR altered NSCLC patients following adjuvant chemotherapy, PD-L1 ≥ 1% is required for atezolizumab use while the administration of pembrolizumab is irrespective of PD-L1 score. The gene discussed is ALK; the disease is non-small cell lung carcinoma.